Clinical and Translational Science Institute
Advancing today’s discoveries to improve health for all.

CTSI Research Showcase

Presenter at the research showcase
presenter at research showcase 2
Research showcase presentation
group of leaders talking
poster presentation
people talking at poster session
group of people talking at poster session
research team with their poster
Group of researchers listening to presentations.

The agenda included presentations from recipients of CTSI Pilot Awards, Clinical and Translational Science Research Program, T32 Training Grants, K12 Career Development Awards and the Path to K, Launch to R and Launch to K programs. These individuals, and their research, represent the future of translational science and the career development and innovation that CTSI proudly supports.

The showcase began with opening remarks from CTSI Director Julie A. Johnson, PharmD, who provided an overview of CTSI’s mission and efforts to support investigators across the translational science spectrum, break down barriers in research and foster interdisciplinary collaboration. Throughout the afternoon, attendees heard from teams addressing pressing health challenges, advancing personalized medicine and leveraging new technologies to improve care for all. The event also celebrated the success of CTSI’s career development initiatives, which have helped dozens of early-career investigators secure additional NIH K and R awards and build a robust pipeline of translational scientists.

After the presentations, attendees gathered for a poster session and reception, connecting with colleagues from across the university to share ideas and celebrate the achievements of the CTSI community. The 2025 CTSI Research Showcase highlighted the institute’s dedication to fostering innovation, collaboration and to support translational scientists throughout their careers.

Julie Johnson, PharmD, is the Director and Principal Investigator at The Ohio State University Clinical and Translational Science Institute. 

Joshua J. Joseph Appointed Deputy Director of CTSI

Concurrent with this appointment in the CTSI, Dr. Joseph serves as Associate Professor of Internal Medicine with Tenure and Endowed Professor for Research in Internal Medicine within the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center. Prior to joining the Wexner Medical Center, he founded and directed the Yale Primary Care Center Weight Management and Wellness Clinic and served as an Instructor of Medicine at Yale University School of Medicine. 

Joshua Joseph

A highly respected endocrinologist, Dr. Joseph’s research specialization is in diabetes and preventing chronic disease through community-based interventions. He has secured over 45 million dollars in research funding from organizations such as the National Institutes of Health, American Heart Association, Agency for Healthcare Research and Quality, Robert Wood Johnson Foundation and the U.S. Department of Defense. He currently leads a national $15 million project within the American Heart Association’s Strategically Focused Research Network on Cardiovascular Kidney Metabolic Syndrome in Women, aiming to uncover why women are at increased risk due to unique life stages and factors.

Dr. Joseph’s scientific and community engagement expertise is highlighted by his role as co-founder and medical director of The Ohio State Wexner Medical Center Healthy Community Center, which focuses on nutrition, physical and mental wellness in Columbus and provides community members a place to build connections and find the health information and support they need to create and sustain lifelong healthy habits. Dr. Joseph also founded the ACCELERATE Research Group, whose work aids in the mission to advance cardiometabolic health for all and has been featured on many national and international platforms, including Time, CBS News, NBC News, ABC News and PBS Newshour.

In addition to his research and community-driven work, Dr. Joseph has served as a keynote speaker at numerous national conferences on heart health, diabetes and community engagement. Notably, he was a featured speaker at the White House’s Inflation Reduction Act Insulin Event, advocating for insulin affordability and policy change as part of the Endocrine Society, in which he is an active member. He serves as President of the Central Ohio American Heart Association Board and Member of the Board of Columbus Public Health.  

Dr. Joseph’s dedication to community health, research and education is reflected in numerous honors, including induction into the Alpha Omega Alpha Honor Medical Society and American Society for Clinical Investigation. He has also received The Ohio State University Early Career Distinguished Scholar Award and Community Engaged Scholar Award, as well as the Endocrine Society’s 2024 Richard E. Weitzman Outstanding Early Career Investigator Award, Columbus Education Association Dr. Martin Luther King Jr. Humanitarian Award and the “Philanthropist of the Year” Pillar Award for Community Service.

Please join us in welcoming Dr. Joshua Joseph as deputy director of the CTSI. His commitment to excellence and visionary leadership will greatly benefit the CTSI’s work as we continue to build innovative partnerships and drive forward our mission to improve health for all.

Julie Johnson, PharmD, is the Director and Principal Investigator at The Ohio State University Clinical and Translational Science Institute. 

Information Session: AIM-AHEAD and NCATS Health Data Science Training Program Class of 2026

Information and Ideation Session - Clinical and Translational Science Research Program Award

2026 Clinical and Translational Science Research Program RFA

Please read all of the RFA instructions below before submitting your application.

Funding 

Up to $125,000 per year in direct costs can be budgeted for a two-year period, for a maximum amount of $250,000. No-cost extensions are not allowed, thus unspent funds are not available past 12 months. 

  • Salary support for faculty may be requested under the following guidelines:
    • Assistant Professor 15% effort up to NIH CAP
    • Associate professor 10% effort up to NIH CAP
    • Full professor 5% effort up to NIH CAP
  • Salary and fringe support for students, graduate students, clinical trainees, post-doctoral and clinical fellows are permitted. 
  • Subcontracts for personnel or services outside Ohio State or Nationwide Children’s Hospital are not permitted.
  • Travel funds are permitted if necessary to conduct the study (e.g., participant travel). No international travel is allowed.
  • Equipment that is essential for the study and not otherwise available may be requested, but equipment expenditures greater than $3,000 are discouraged. 

A notice of intent to fund will be sent in February 2026 and will be subject to NCATS prior approval. Contingent on NCATS prior approval, funds will be available beginning August 1, 2026.

Support for dissemination of validated methods across the regional and national CTSA networks for broader translational science impact will be provided to awardees.

 

Eligibility Requirements

PERSONNEL

  • Applicants must have Principal Investigator (PI) status as defined by The Ohio State University or Nationwide Children’s Hospital.
  • PIs are required to be members of CTSI before submitting an application. Join the CTSI 
  • Applicants cannot have had a CTSI pilot award that activated on or after August 1, 2024, or a Research Program award that activated on or after August 1, 2023.
  • Prior to submitting a full application, all applicants must complete all necessary research training (Responsible Code of Research, Human Subject Protection and Good Clinical Practice) if the proposed project involves human subjects. 

PROJECTS

  • Proposals must develop new concepts, methods, technologies, or research practices that drive translational science, and should clearly identify the translational science challenges or barriers that their proposal addresses.
  • Proposed work must be innovative, equitable and generalizable.

  • Proposed work must be completed within two years. The NIH does not allow no cost extensions on these funds. Feasibility for completing the work within 24 months will be an important review criterion.

     

Application and Review Process 

PRE-APPLICATIONS

A pre-application is required and must be submitted via REDCap in the following format: 

  • REDCap Form
    • Lead PI Information
    • Co-PI Information
    • Other Co-Investigators
    • Project Description
    • Translational Science Statement
    • Regulatory Considerations
    • Budget (non-itemized)
    • External Collaborators
  • 1-Page Abstract of the proposed work that includes the questions and translational challenges addressed, significance, methods and specific aims
  • MPI NIH Biosketch(es)

Directors of the Clinical and Translational Science Research Program review pre-applications to the Clinical and Translational Science Research Program and evaluate for significance, innovation and relevance. Selected projects will be invited for full applications.

FULL APPLICATIONS

Full applications are by invitation only. Invitations and a link to the REDCap full application form will be emailed the week of September 23, 2025.

CTSI participates in a national Center for Translational Science Award External Reviewer Exchange Consortium to improve fairness in the scientific review process and better match applicants with feedback from experts in their respective fields. Trained patient and practitioner reviewers are also included in the grant review process. In submitting an application, you agree to allow reviewers external to The Ohio State University and Nationwide Children’s Hospital to access to your application materials. 

Applications will be sent to 1-2 external reviewers with expertise in the subject matter and scored on the review criteria using the NIH 9-point scale. Applications will then be assessed in an NIH-type study section that takes into consideration external reviewer feedback, institutional context, and relevance to the CTSI mission.

Applications selected for funding are subject to NCATS prior approval before the release of funds. Teams selected for funding are required to meet with CTSI Regulatory Program Manager April Green before February 24, 2026, regarding the pre-approval submission process.

IMPORTANT INFORMATION

IRB approval or determination of non-human subject research is required for NCATS Prior Approval submission. IRB submission must be submitted by March 31, 2026, or the offer for funding will be withdrawn.

Timeline

Mandatory Pre-Applications Due

Sept. 30, 2025
Submission window: Sept. 20-30

Invitations to Submit Full Application

Oct. 6, 2025
By Invitation Only

Full Applications Due

Nov. 24, 2025
Late applications will not be accepted.

Notice of Intent to Fund

February 2026
Notifications will be sent out.

Mandatory Consult with CTSI Regulatory Program Manager Due

March 15, 2026
Regulatory Program Manager: April Green

IRB Submission Due

March 31, 2026
Late submissions will not be accepted

NCATS Prior Approval Documents Due to Regulatory Manager

June 15, 2026
Regulatory Program Manager April Green

Award Start Date

Aug. 1, 2026
Contingent upon NCATS prior approval

T32 Grant Application Checklist

T32 Grant Application Checklist

The Application consists of several parts. Please use this form as a checklist when preparing your application. The application must be completed online, with additional materials uploaded in PDF format the application.

The following information will be provided in an on-line form at the web address noted above.

  • Personal Information

(Includes Employee ID Number; Ohio State University name.#; ORCID Id [see orcid.org], ERA commons name)

  • Campus Address
  • Current University Employment Information
  • Applicant Eligibility checklist (see below for more information)
  • Research Eligibility checklist (see below and Appendix 1 for more information)

The following information must be provided in a single PDF document uploaded to the application form.

  • Cover Page 
    • Name
    • Graduate Program(s)
    • Proposed Research Project Title
    • Research Project Abstract (250 words)
    • Mentoring Team
  • Mentoring and career development plan (up to 2 pages)
    • Applicant's Background
    • Career Development/Training Activities 
    • Mentoring ( see below for more information)
  • Proposed Research Plan (up to 4 pages)            
  • Title
  • Statement of significance of the research problem
  • Specific Aims of the Project
  • Research Methods
  • How the research is expected to impact health for all
  • References (not included in the page limit)
  • Signature page 
  • Applicant 
  • Primary Mentor
  • Graduate Program Chair
  • Letters of support from your Primary mentor and the other members of your mentorship team.
  • NIH Biosketches
    • Applicant
    • Mentoring Team: Primary Mentor and two other mentors (and any additional optional mentors you have)
  • Current Advising Report (which should include GRE, MCAT or equivalent test results)

Predoctoral T32 RFA and Application Information

Please download and read all of the T32 RFA instructions below before submitting your application.

Call for Applications to the Clinical and Translational Science Institute's Predoctoral T32 Mentored Career Development Grant

The T32 grant provides full-time research training support for predoctoral trainees pursuing mentored clinical and translational research or clinical and translational science who are enrolled in any Ohio State graduate degree program and are postcandidacy. Examples of potential projects include research focused on advancing therapeutics, developing new clinical interventions, proof of concept studies, investigating/fostering behavior modifications to improve health, health outcomes research, etc. 

Letter of Intent Due Date

November 3, 2025, 11:59 p.m.

Submit Your LOI

Application Due Date

December 19, 2025, 11:59 p.m.

Apply Here

Notice of Award Date

April, 2026

Benefits of the T32 Program

  • Stipend support will be awarded at the NIH allowed annual maximum
  • Coverage of tuition and fees
  • Access to the CTSI professional services and staff including biostatistics, research participant recruitment and retention services, and regulatory support
  • Access to a training curriculum in clinical and translational research methodology and specialized training seminars

For this cycle, three predoctoral awards will be made.

Download the Full RFA

Funding Opportunity Purpose

The Clinical and Translational Science Institute (CTSI) is calling for applications to the Predoctoral T32 mentored research training program. 

The goal of this predoctoral training program is to leverage the large, collaborative and multidisciplinary research environment at Ohio State to increase the reach of clinical and translational science (CTS) education and training across The Ohio State University campus and to recruit and develop a diverse cohort of trainees to become the next generation of clinical and translational scientist leaders.

The T32 grant provides full-time research training support for predoctoral trainees pursuing mentored clinical and translational research or clinical and translational science who are enrolled in any Ohio State graduate degree program and are postcandidacy. Examples of potential CTS projects include research focused on advancing therapeutics, developing new clinical interventions, promoting health for all or investigating/fostering behavior modifications to improve health. 

Predoctoral trainees in clinical/translational related graduate degree programs (such as in the Colleges of Medicine, Public Health, Engineering, Nursing, Veterinary Medicine and others; and interdisciplinary programs such as Neuroscience and Nutrition) and health-professional doctorate trainees who are enrolled in a Master’s or Doctoral program (such as MPH, MMS or MD/PhD program) are also eligible to apply.

The overall goal of the T32 program is to increase the number of well-trained biomedical researchers who can lead the design and oversight of future clinical and translational investigations critical to transforming the translational process so that new treatments and cures for disease can be delivered to patients faster and efficiently to all affected populations. 

Download the Full RFA

Contacts

Stuart D. Hobbs, PhD, MBA

Program Director, Education and Training

Email

stuart.hobbs@osumc.edu

Ginny L. Bumgardner, MD, PhD

T32 Program Director

Associate Dean for Physician Scientist Education and Training, and Professor of Surgery, College of Medicine

Email

Ginny.Bumgardner@osumc.edu 

Sakima Smith, MD, MPH

T32 Assistant Program Director

Associate Professor, College of Medicine; Department of Internal Medicine

Email

sakima.smith@osumc.edu

What Can CoMS Do For You? Seminar with Matt Sullivan

Physics and Quantum Information Talk: Dual-Species Neutral Atom Quantum Processors

Women's Health Research Symposium

Subscribe to